Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 10/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850527 | 0.92 | GPR52 (0.61) | GPR52S1PR5SCDCNR1CNR2 | |
| SCHEMBL3217763 | 0.90 | GPR52 (0.68) | GPR52S1PR5TP53SNCAS1PR4 | |
| SCHEMBL13489525 | 0.90 | GPR52 (0.59) | GPR52S1PR5SCD | |
| SCHEMBL3223345 | 0.88 | GPR52 (0.71) | GPR52SCDTP53 | |
| SCHEMBL3211306 | 0.84 | GPR52 (0.60) | GPR52S1PR5TP53S1PR4 | |
| SCHEMBL1851568 | 0.84 | GPR52 (0.78) | GPR52S1PR5SNCAS1PR4 | |
| SCHEMBL1848008 | 0.84 | GPR52 (0.51) | GPR52S1PR5S1PR4 | |
| SCHEMBL3215617 | 0.80 | GPR52 (0.60) | GPR52SCDS1PR4 | |
| SCHEMBL3208649 | 0.79 | GPR52 (0.57) | GPR52S1PR5SCDCNR1CNR2 | |
| SCHEMBL1853387 | 0.79 | GPR52 (0.79) | GPR52SCDTP53LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885S1PR5 696/4885SCD 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.